6 studies found for:    regorafenib AND GIST | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
2 Available Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (BAY73-4506)
3 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
4 Recruiting A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
5 Recruiting Stivarga Regulatory Post-Marketing Surveillance Study in Korea
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (Stivarga,BAY73-4506)
6 Recruiting FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: Regorafenib;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin

Indicates status has not been verified in more than two years